Twenty-five years ago, the cytotoxic drug irinotecan (IRT) was first approved in Japan for the
treatment of cancer. For more than two decades, the IRT prodrug has largely contributed to …

Irinotecan has been used in the treatment of various malignancies for many years. Still, the
knowledge regarding this drug is expanding. The pharmacogenetics of the drug is the …

Pancreatic cancer is one of the harshest and most challenging cancers to treat, often labeled
as incurable. Chemotherapy continues to be the most popular treatment yet yields a very …

Simple Summary Organometallics, such as copper compounds, are cancer
chemotherapeutics used alone or in combination with other drugs. One small group of …

Liposomal irinotecan (nal-IRI; Onivyde®; also known as pegylated liposomal irinotecan) has
been developed with the aim of maximising anti-tumour efficacy while minimising drug …

Desmoplasia is characteristic of pancreatic ductal adenocarcinoma (PDAC), which exhibits
5‐year survival rates of 3%. Desmoplasia presents physical and biochemical barriers that …

Pancreatic tumors grow in an “austerity” tumor microenvironment characterized by nutrient
deprivation and hypoxia. This leads to the activation of adaptive pathways in pancreatic …

In this report, a novel irinotecan (IR) encapsulated redox-responsive liposome was
developed. The redox-responsive liposomes were prepared based on disulfide …

Pancreatic adenocarcinoma has the worst outcome among all cancer types, with a 5-year
survival rate as low as 10%. The lethal nature of this cancer is a result of its silent onset …

Pancreatic cancer (PC) is the seventh most frequent cause of cancer-related deaths
worldwide with a high mortality. MicroRNAs (miRNAs) act as important regulators for the …